Insider Selling: Charles River Laboratories International (NYSE:CRL) CEO Sells $1,819,350.00 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) CEO Birgit Girshick sold 6,500 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the transaction, the chief executive officer directly owned 36,013 shares in the company, valued at $10,080,038.70. The trade was a 15.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Trading Down 0.9%

Shares of Charles River Laboratories International stock traded down $2.59 during trading on Thursday, hitting $281.78. 1,054,824 shares of the company were exchanged, compared to its average volume of 929,021. The firm has a market capitalization of $13.45 billion, a P/E ratio of -58.10, a price-to-earnings-growth ratio of 2.92 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $288.02. The firm’s fifty day moving average price is $220.98 and its 200 day moving average price is $190.27. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same period last year, the company posted $3.12 EPS. Charles River Laboratories International’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

CRL has been the topic of a number of recent analyst reports. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Morgan Stanley raised their price objective on Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Evercore reiterated an “outperform” rating on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Robert W. Baird set a $291.00 target price on Charles River Laboratories International in a research note on Thursday, August 6th. Finally, Mizuho set a $264.00 price target on Charles River Laboratories International in a report on Monday. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $255.65.

Institutional Investors Weigh In On Charles River Laboratories International

Several large investors have recently made changes to their positions in the stock. Cardinal Capital Management grew its holdings in shares of Charles River Laboratories International by 0.6% during the fourth quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock worth $2,180,000 after purchasing an additional 62 shares in the last quarter. Asset Management One Co. Ltd. raised its stake in Charles River Laboratories International by 4.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock valued at $375,000 after purchasing an additional 71 shares in the last quarter. Glenmede Trust Co. NA lifted its position in Charles River Laboratories International by 2.8% during the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock valued at $467,000 after purchasing an additional 73 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its stake in Charles River Laboratories International by 1.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock worth $1,260,000 after buying an additional 80 shares in the last quarter. Finally, Advisory Services Network LLC grew its stake in Charles River Laboratories International by 2.6% in the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after buying an additional 83 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.